GSK Completes Breo Ellipta Asthma Study For Potential NDA Filing
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK reports positive results of a Phase III trial comparing the once-daily corticosteroid/long acting beta2-agonist combination Breo to the corticosteroid alone.
You may also be interested in...
GSK’s Breo Ellipta Marches Forward For Asthma, Efficacy Undistinguished From Advair
Follow-on may continue to face adoption challenges with expanded indication despite dosing convenience.
GSK’s Breo Ellipta Marches Forward For Asthma, Efficacy Undistinguished From Advair
Follow-on may continue to face adoption challenges with expanded indication despite dosing convenience.
GSK’s Big Push To Maintain Its Respiratory Reign
GlaxoSmithKline is counting on new products like Breo Ellipta and Anoro Ellipta to extend its legacy in respiratory disease beyond Advair Diskus, which could face generic competition within the next five years. But GSK may need to wage a battle on the reimbursement front before it can claim commercial success – a challenge highlighted by Express Scripts’ unexpected decision to put Advair and Breo on its not covered list for 2014.